

SEC  
04 AL

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>Marc B. Samuels</b>			
2. Address <input type="checkbox"/> Check if different than previously reported <b>823 Congress, Suite 900</b>			
3. Principal Place of Business (if different from line 2) <b>Austin TX</b> City: State/zip (or Country)			
4. Contact Name <b>Linda Lucko</b>	Telephone <b>(512) 480-8962</b>	E-mail (optional)	5. Senate ID #
7. Client Name <input type="checkbox"/> Self <b>Pharmaceutical Research &amp; Manufacturers of America</b>			6. House ID # <b>35506006</b>

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30) ☒ OR Year End (July 1-Dec)9. Check if this filing amends a previously filed version of this report ☐10. Check if this is a Termination Report ☐ ⇌ Termination Date \_\_\_\_\_

11. No Lobbyin

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<b>12. Lobbying Firms</b>  <b>INCOME</b> relating to lobbying activities for this reporting period was:  Less than \$10,000 <input checked="" type="checkbox"/>  \$10,000 or more <input type="checkbox"/> ⇌ \$ _____ Income (nearest \$20,000)  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>13. Organizations</b>  <b>EXPENSES</b> relating to lobbying activities for this report period were:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input type="checkbox"/> ⇌ \$ _____ Expenses (nearest \$20,000)  <b>14. REPORTING METHOD.</b> Check box to indicate ex accounting method. See instructions for description of o
<input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definiti <input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033 Internal Revenue Code <input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162( Internal Revenue Code	

Signature

Date **08/02/04**

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_ Marc B. Samuels \_\_\_\_\_

LD-2 (REV. 4/03)

PAGE 1 of 6

Registrant Name Marc B. Samuels Client Name Pharmaceutical Research & Manufacturers of America

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Legislation and regulatory issues related to the Food and Drug Administration (FDA); FDA approval and regulation of biologics and drugs; Medicaid and Medicare coverage of biologics and drugs

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Centers for Medicare and Medicaid Services  
Department of Health and Human Services  
Executive Offices of the President  
Office of Management and Budget  
Federal Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Marc B. Samuels	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature



Date

08/02/04

Printed Name and Title marc B. Samuels

Form LD-2 (Rec. 4/03)

Page 2

Registrant Name Marc B. Samuels Client Name Pharmaceutical Research & Manufacturers of An

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Legislation and regulatory issues related to the Food and Drug Administration (FDA); FDA approval and regulation of biologics and drugs; Medicaid and Medicare coverage of biologics and drugs


17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Centers for Medicare and Medicaid Services  
Department of Health and Human Services  
Executive Offices of the President  
Office of Management and Budget  
Federal Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Marc B. Samuels	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature  Date 08/02/04

Printed Name and Title Marc D. Sanders

Form LD-2 (Rev. 4/03)

Page 3